Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ('BriaCell” or the 'Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, ...

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration.

Poster presentation of updated data on BT-001 from the Phase 1 part of the ongoing Phase 1/2a study in solid tumors - LUND, SE / ACCESS Newswire / July 28, 2025 / BioInvent International AB ("BioInven ...

HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep” or 'the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for ...

National conference titled Connectomics-2025, focusing on the convergence of Omics, Bioinformatics, and Data Science for modern medical research, inaugurated ...

Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and ...

Researchers sought to determine whether bosutinib would be safe and effective in treating pediatric patients with Ph+ CML.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

The national conclave on ‘Emerging Trends in Bio-manufacturing and Healthcare – 2025,’ organised by CSIR-NIIST, called for science-based solutions to address healthcare challenges in both urban and ...

Cash Position: GeoVax reported cash balances of $3,093,862 at June 30, 2025, as compared to $5,506,941 at December 31, 2024. During July 2025, the Company completed a public offering of common stock ...